Oric Pharmaceuticals | 10-Q:2024财年二季报
Oric Pharmaceuticals | 8-K:ORIC 制药公布2024年第二季度财务业绩和运营最新情况
Oric Pharmaceuticals | 4:持股变动声明-董事 Kunkel Lori Anne
Oric Pharmaceuticals | 4:持股变动声明-董事 You Angie
Oric Pharmaceuticals | 4:持股变动声明-董事 Hoerter Steven L.
Oric Pharmaceuticals | 4:持股变动声明-董事 Dier Mardi
Oric Pharmaceuticals | 4:持股变动声明-董事 Heyman Richard A.
Oric Pharmaceuticals | 8-K:重大事件
Oric Pharmaceuticals | 4:持股变动声明-董事 Kunkel Lori Anne
Oric Pharmaceuticals | 10-Q:2024财年一季报
Oric Pharmaceuticals | 8-K:ORIC 制药公布2024年第一季度财务业绩和运营最新情况
Oric Pharmaceuticals | ARS:年度报告
Oric Pharmaceuticals | DEFA14A:其他
Oric Pharmaceuticals | DEF 14A:股东委托书决议
Oric Pharmaceuticals | S-8:员工福利计划证券登记
Oric Pharmaceuticals | 8-K:重大事件
Oric Pharmaceuticals | S-3ASR:“知名成熟发行人”证券注册声明
Oric Pharmaceuticals | 10-K:2023财年年报
Oric Pharmaceuticals | 8-K:ORIC Pharmicals公布2023年第四季度和全年财务业绩和运营最新情况
Oric Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-FMR LLC(7.562%),Abigail P. Johnson(7.562%)
暂无数据
暂无数据